Uscom Ltd news

A recent study confirms the high accuracy of the Uscom BP+ central blood pressure monitor for detection of the dangerous cardiac rhythm abnormality Atrial Fibrillation (AF) in a primary care setting. This result confirms that BP+ suprasystolic oscillometry is 94% effective for detection of AF in home care environments and may be used as a screening investigation.

Russian regulatory certification for USCOM 1A Cardiac Output Monitor, Russia a significant and growing European market, Uscom continues global expansion. USCOM 1A has received Russian Certification of Registration for sale into the Russian market. The regulatory process is usually 12-18 months but took approximately 3 years following delays with the COVID pandemic. Uscom has worked closely with our experienced Russian distributor, Wondermed, to successfully manage thi

Patent protected wireless lung function testing technology, Asthma, COPD, and post-COVID syndrome, Spirometry market is predicted to double in 12 months, Globalisation initiative – Europe, SE Asia and the US. Uscom notifies the market of notice to approve CE mark for the Uscom digital ultrasonic SpiroSonic AIR spirometer. The CE mark is recognition of legal compliance with health, safety and environmental standards set by the European Community, and is esse

Uscom has completed the development of two new specialised cardiovascular monitors, the “USCOM O2” and the “USCOM Basic”. The development of these two new monitors creates for Uscom a three-tier range of Uscom haemodynamic monitors for sale into China. Uscom is required to obtain regulatory approval of the China National Medical Products Administration (NMPA) for the two new specialised cardiovascular monitors prior to the commencement of sales. The